首页> 美国卫生研究院文献>Open Access Macedonian Journal of Medical Sciences >Drug-Induced Melanoma: Irbesartan Induced Cutaneous Melanoma! First Description in the World Literature!
【2h】

Drug-Induced Melanoma: Irbesartan Induced Cutaneous Melanoma! First Description in the World Literature!

机译:药物诱导的黑色素瘤:厄贝沙坦诱导的皮肤黑色素瘤!世界文学的第一个描述!

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND:Melanoma appears to be a malignant disease, whose development can be potentiated by different drug groups. More and more data are in favour of the claim that commonly used antihypertensive drugs also contain the risk of developing melanoma. The most evidence is that angiotensin receptor blockers may be carcinogenic. Two representatives from this group, valsartan and irbesartan, produced by certain pharmaceutical companies are being withdrawn from the market due to finding content of NDMA and NDEA, which are believed to be potent carcinogens. Another representative of this group, losartan, according to in vitro data, potentiates cell adhesion and invasion of human melanoma cells.
机译:背景:黑色素瘤似乎是一种恶性疾病,其发展可以通过不同的药物组来加强。越来越多的数据支持这种说法,即常用的降压药也有发展黑色素瘤的风险。最有证据表明,血管紧张素受体阻滞剂可能是致癌的。某些制药公司生产的该组的两名代表,缬沙坦和厄贝沙坦,由于发现了NDMA和NDEA的含量而被撤出市场,NDMA和NDEA被认为是强致癌物。根据体外数据,该组的另一种代表是氯沙坦,可增强细胞黏附和对人黑素瘤细胞的侵袭。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号